Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV₁. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255 .).
No takes yet. Share an insight, caveat, or question.
Nair et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: